Skip to main content
Psychedex

6Node page

what any key link opens

psx:substance/tetrahydrocannabihexol/search/900adf03-bce0-4b09-9d7c-214d3d42f8a3

search2026-05-13recorddocument_retrieval

derived from · upstream

none recorded

feeds · downstream

Closure of psx:substance/tetrahydrocannabihexol/search/900adf03-bce0-4b09-9d7c-214d3d42f8a3: 37 upstream, 58 downstream.

psx:substance/tetrahydrocannabihexol/search/900adf03-bce0-4b09-9d7c-214d3d42f8a3
  ├─ used  search/4ffeb7d9-b9c2-4c2f-b536-3f1f56ddc054  Searched PubMed for "tetrahydrocannabihexol THCH cannabinoid"
  ├─ used  search/e8d49810-6e20-4d3e-b96f-3e1817a0f300  Searched OpenAlex for "tetrahydrocannabihexol THCH"
  ├─ used  search/bd76bb9e-1187-46d3-bc04-56107a2db0ee  Searched PubChem for "tetrahydrocannabihexol / delta-9-tetrahydrocannabihexol / THCH cannabinoid hexyl"
  ├─ used  search/259e653e-5532-47e1-8c8a-475bdf886baa  Searched ClinicalTrials.gov for "tetrahydrocannabihexol THCH"
  ├─ used  search/871fd3c0-b2bd-40cd-9dd8-09c4652c1b15  Searched PubChem for "CID 161906 (direct lookup)"
  ├─ used  search/46679466-88cc-4130-b65e-fe741e0f0324  Searched WebSearch for "tetrahydrocannabihexol THCH PubChem CID molecular formula SMILES"
  ├─ used  search/f0bcf1d7-63b5-4dec-b0dd-1b4901b2f958  Searched HandWiki for "Tetrahydrocannabihexol chemistry page"
  ├─ used  search/d2e5d0f5-9487-4459-80bb-a5e5b009ac6b  Searched WebSearch for "Roger Adams parahexyl n-hexyl THC synthesis 1942 1949 cannabinoid history"
  ├─ used  search/297b66bd-189f-4997-b06c-6e2622c61a6d  Searched ClinicalTrials.gov for "tetrahydrocannabihexol THCH"
  ├─ used  search/201c62ec-630c-4a55-baab-9010747afb71  Searched WebSearch for "THCH tetrahydrocannabihexol legal status scheduling DEA US UK EU 2024"
  ├─ used  search/71f093b3-c4c0-4cdd-97b2-64b8dfcbebab  Searched WebSearch for "THCH tetrahydrocannabihexol adverse effects toxicity hospitalization case report 2023 2024"
  ├─ used  search/63991fa5-2e77-46ee-bd53-9c08c37be169  Searched PubMed for "Russo Vandelli HHC hexahydrocannabinol synthesis pharmacological epimers 2023"
  ├─ used  search/265ac301-5320-48d8-8231-4acaca1e4b6a  Searched WebSearch for "THCH tetrahydrocannabihexol CB1 Ki binding affinity nM receptor pharmacology published study"
  ├─ used  search/fa5994b3-45a9-425d-9b08-9e2d86c343e0  Searched WebSearch for "UK ACMD semi-synthetic cannabinoids THCH scheduling recommendation 2025"
  ├─ used  search/d137b5ed-df35-435e-b729-8f152983f84a  Searched Japan National Consumer Affairs Center
  ├─ used  search/d5128cd9-9225-4665-afe4-c492ef0a3126  Searched PubMed for "similarities differences THC derivatives cannabinoid CB1 CB2 binding phytocannabinoids 2021"
  ├─ used  search/f36bbe20-178a-46fc-a092-8216fecb8fdc  Searched HandWiki for "Tetrahydrocannabihexol chemistry"
  ├─ used  search/9b259dfa-c789-49f3-999a-8dd3696d6ac1  Searched Multi-source for "THCH CB1 Ki EC50 binding affinity cross-reference"
  ├─ used  search/aaa59c06-a52c-4e3b-ac99-a503254772d2  Searched Multiple sources synthesis for "THCH legal status compilation"
    ├─ used  src/doi:10.1007/s00204-024-03769-4  Investigation of the intrinsic cannabinoid activity of hemp-derived and semisynthetic cannabinoids with β-arrestin2 recruitment assays - and how this matters for the harm potential of seized drugs
    ├─ used  src/doi:10.1038/s41598-020-79042-2  Identification of a new cannabidiol n-hexyl homolog in a medicinal cannabis variety with an antinociceptive activity in mice: cannabidihexol
    ├─ used  src/doi:10.1002/dta.3777  Discrepancies between the stated contents and analytical findings for electronic cigarette liquid products: Identification of the new cannabinoid, Δ9-tetrahydrocannabihexol acetate
    ├─ used  src/doi:10.4137/PMC.S32171
    ├─ used  src/url:414164d7caaece3f  Cannabinoid THCH is designated substance! Never obtain and use products including THCH
    ├─ used  src/url:37526dc53c27b158  Parahexyl (Synhexyl) — synthesis and early pharmacological history
    ├─ used  src/doi:10.1038/s41598-019-56785-1  A novel phytocannabinoid isolated from Cannabis sativa L. with an in vivo cannabimimetic activity higher than Δ9-tetrahydrocannabinol: Δ9-Tetrahydrocannabiphorol
    ├─ used  src/doi:10.1248/yakushi.24-00029  Identification of Δ8-THC and Δ9-THC Analogs with Different Alkyl Chain Lengths in Oil Products Distributed on the Internet
    ├─ used  src/url:e3a06ae8877bbd1c  Semi-synthetic cannabinoids related to tetrahydro-cannabinol and cannabidiol — ACMD report and government response
    ├─ used  src/doi:10.3390/molecules26092774  Cannabinoids, Phenolics, Terpenes and Alkaloids of Cannabis
    ├─ used  src/pmid:10454479  Manipulation of the tetrahydrocannabinol side chain delineates agonists, partial agonists, and antagonists
    ├─ used  src/doi:10.1016/j.phrs.2021.105970  Similarities and differences upon binding of naturally occurring Δ9-tetrahydrocannabinol-derivatives to cannabinoid CB1 and CB2 receptors
    ├─ used  src/pmid:2853671  Metabolism of n-hexyl-homologues of delta-8-tetrahydrocannabinol and delta-9-tetrahydrocannabinol in the mouse
    ├─ used  src/doi:10.1093/jat/bkaf023  Comprehensive LC-MS-MS analysis of THC isomers, analogs, homologs, and metabolites in blood and urine
    ├─ used  src/doi:10.1093/jat/bkaf095  Rapid LC-QTOF-MS screening method for semi-synthetic cannabinoids in whole blood
    ├─ used  src/doi:10.1093/jat/bkae036  Cross-reactivity of 24 cannabinoids and metabolites in blood using the Immunalysis Cannabinoids Direct enzyme-linked immunosorbent assay
    ├─ used  src/doi:10.1159/000536339  Cannabidiol-Derived Cannabinoids: The Unregulated Designer Drug Market Following the 2018 Farm Bill
    └─ generated_by  pub/d53c3392-d8d4-424d-a87c-0211cea9b8a6  Publication — backfill
├─ used  gen/77994829-f8b3-46c5-bc69-d63935f2ea83  Generation — pipeline-v5
  ├─ derived_from  version/1  Revision 1
    ├─ derived_from  issue/notice@be4a9d59ca14  Issued notice
    ├─ derived_from  issue/info_card@588d291229c8  Issued info_card
    ├─ derived_from  issue/emergency@207cf682e28a  Issued emergency
    ├─ derived_from  issue/info_card@4a6ebe242359  Issued info_card
    ├─ derived_from  issue/emergency@7386375eac13  Issued emergency
      ├─ used  claim/19ffb11d-145b-40e6-a7a4-39713b7acf87  Claim in summary — supported
      ├─ used  claim/a8ef881b-4e1e-49ce-9d78-ab4329addc03  Claim in summary — partially_supported
      ├─ used  claim/a34a0cf9-1373-465a-a3c8-f7fc1e1c6784  Claim in pharmacology — supported
      ├─ used  claim/4d90af1a-1349-4838-9233-3667b344b916  Claim in pharmacology — partially_supported
      ├─ used  claim/c1af14fd-8e38-44d5-8cd0-5cfd3e462dee  Claim in safety — supported
      ├─ used  claim/fdb61dda-5e7d-411a-87d7-23ec91948c59  Claim in receptor-pharmacology — supported
      ├─ used  claim/b0d60066-f566-4d9f-b5ee-8562406ab314  Claim in receptor-pharmacology — supported
      ├─ used  claim/d65bc393-05eb-462f-b8e4-79933185cc93  Claim in clinical-evidence — supported
      ├─ used  claim/c59aef73-67a1-4a83-b5d3-faabe14e38f2  Claim in comparative-pharmacology — supported
      ├─ used  claim/5f9b2191-1219-4a94-a660-e99e215e9c5e  Claim in comparative-pharmacology — supported
      ├─ used  claim/9567bc99-f137-4100-973c-e2499b42746e  Claim in neuroscience — supported
      ├─ used  claim/41f40c44-884c-4c6f-b93d-7b6bbc9d0422  Claim in summary — supported
      ├─ used  claim/ca2aaa91-c21a-412a-b78a-028c99f18481  Claim in chemistry — supported
      ├─ used  claim/e370cadd-c0f0-48bc-9b8f-0050a141c148  Claim in history — supported
      ├─ used  claim/27699e0c-1013-4519-a792-e674a20219aa  Claim in chemistry — inconclusive  working
      ├─ used  claim/7d9c088f-6555-4c86-8abe-f26733d1d2d4  Claim in chemistry — supported
      ├─ used  claim/1b49de0b-52ec-4453-9919-ba3777b64f62  Claim in chemistry — supported
      ├─ used  claim/2bb27cf0-0518-4921-a658-ea94443cfb76  Claim in clinical-evidence — supported
      ├─ used  claim/ec19557b-17d9-4f81-890a-c19ba6930d85  Claim in summary — not_supported  working
      ├─ used  claim/2ed7683c-7b16-4dde-89bb-74b1b041c692  Claim in safety — supported
      ├─ used  claim/24cf2c3b-f839-4256-9404-f8c8ffb1d928  Claim in safety — partially_supported
      ├─ used  claim/c8ba3f42-c021-4abc-a924-ac80d49397b0  Claim in safety — supported
      ├─ used  claim/ba243eb8-8f4a-46c9-af42-9f6d4b7a271d  Claim in history — inconclusive  working
      ├─ used  claim/b47d1d9b-1280-4875-85fe-62baeae6c58a  Claim in history — supported
      ├─ used  claim/8eaf1333-60e3-4867-9a7b-f5e6e7eb579b  Claim in summary — supported
      ├─ used  claim/8ebaec84-1e7d-4d78-99a8-954dab969ad4  Claim in pharmacology — supported
      ├─ used  claim/5b245cd6-b86c-4614-9e73-33f65898a33e  Claim in pharmacology — inconclusive  working
      ├─ used  claim/25a06938-7096-4d02-a049-292a9145ff29  Claim in comparative-pharmacology — supported
      ├─ used  claim/fee15854-2661-4abe-9d9d-c52db08859bf  Claim in chemistry — supported
      ├─ used  claim/52ecffff-741f-46d5-af4b-3ad69d499045  Claim in chemistry — supported
      ├─ used  claim/1a44b125-0c42-445b-af57-64b71fa5101a  Claim in receptor-pharmacology — supported
      ├─ used  claim/eedb14e7-9000-4a59-ad24-2b6bb9d7c4af  Claim in receptor-pharmacology — inconclusive  working
      ├─ used  claim/e731a9e0-cfe8-46b2-8e88-06f6a91d9a2f  Claim in history — partially_supported
      ├─ used  claim/d4ff50e7-cf26-4aaa-8e9a-ed592adf6e99  Claim in safety — supported
      ├─ used  claim/07dc5fc4-9075-4511-9d8c-9e0d757d24cb  Claim in history — partially_supported
      ├─ used  claim/80918fd7-561d-4640-b490-de15bf8a5e87  Claim in history — supported
      ├─ used  claim/5386f09f-f002-4088-b5ee-f828e5367527  Claim in chemistry — supported
      ├─ used  claim/e8bff07f-871e-4446-bbaf-b070c6881537  Claim in pharmacology — supported
      ├─ used  claim/fd84eedb-7c89-4174-9de8-7f71e3db642a  Claim in receptor-pharmacology — supported
      ├─ used  claim/7dde2b4b-d64b-41c7-87ac-9a2a97a44d3c  Claim in comparative-pharmacology — supported
      ├─ used  claim/35c5af8c-9a8b-461a-bd9d-a65d857ed27f  Claim in pharmacology — supported
      ├─ used  claim/ce7ff999-2499-45e1-a378-7784e4e24216  Claim in pharmacology — supported
      ├─ used  claim/7c3be470-3a4d-4833-ad25-b6f15028f2c4  Claim in pharmacology — supported
      ├─ used  claim/7683ab85-05f0-4072-a2a8-33d322dda625  Claim in pharmacokinetic-detail — supported
      ├─ used  claim/4543fab1-9cd6-4fdb-8ba1-b20692da55d3  Claim in clinical-evidence — supported
      ├─ used  claim/a935038d-8a19-49c7-9ab9-a1845c813624  Claim in safety — inconclusive  working
      ├─ used  claim/c1efaa92-17c5-4e83-bda7-7e63307d8e5d  Claim in pharmacokinetic-detail — partially_supported
      ├─ used  claim/447c051a-74f0-4732-8449-83e0ea3774d7  Claim in safety — inconclusive  working
      ├─ used  claim/3f50acd3-0935-44b8-b045-3cbe4765cb7d  Claim in pharmacokinetic-detail — supported
      ├─ used  claim/50deecfc-0e5e-477a-8fbb-2e6f1e293ab2  Claim in safety — supported
      └─ used  claim/60aaf605-a116-4718-834d-7848022b1ad8  Claim in legal-status — supported
… closure truncated at 200 nodes

indented by distance from this node, not by parentage

1Provenance card

the boundary, as counts

Sources

1712 with DOI

5 strong · 9 moderate · 3 weak

Compilations

22026-05-13T00:21:37.871Z

pipeline-v5 · prompt hash not recorded — run predates 2026-09

Decisions

18last ruled 2026-06-04

0 awaiting a ruling

Issued documents

52026-10-19T20:34:08.367Z

notice · info card · emergency

Searches

204 with no results

queries and counts on the build

Claims checked

5144 supported

44 supported · 7 not

Correspondence

0received

consent field ships in Phase 4

Edges

172

derivations recorded for this entity

Complete over 17 sources, 2 compilations, and 18 decisions.Not here: the private journal (never).Working material — drafts, discards, unsupported claims — is listed below and readable on the working page.Cite: psychedex.org/substances/tetrahydrocannabihexol/archive

2Build

one panel per compilation run

generation run 2026-05-11

8 min failedmodel not recordedplan not recordedrun/412afb1c…

research

no artifact

draft

no artifact

audit

no artifact

verify

no artifact

simplify

no artifact

publish

no artifact

Selection

results seen0
selected by the model0
consumed as sources17

Verification

claims checked0
supported0
partially supported0
not supported0
inconclusive0
  • record
  • seen / partial
  • working

The model's own caveats

none raised on this run

Reproduce

inputs
17 source keys (listed under Sources)
plan
not recorded — template version, prompt hash and git SHA are written from 2026-09 onward
model
not recorded
streams
none — agent transcripts are persisted from 2026-09 onward

generation run 2026-05-13

56 min completedmodel pipeline-v5plan not recordedrun/b60e636c…

research

citationsRegistryrecordresearchOutputworking

draft

articleDraftworking

audit

articleAuditedworking

verify

verificationResultworking

simplify

articleSimplifiedworking

publish

runMetarecordrunSummaryrecord

Selection

results seen94
selected by the model35
consumed as sources17

Verification

claims checked51
supported38
partially supported6
not supported1
inconclusive6
  • record
  • seen / partial
  • working

The model's own caveats

  • sparse_evidence
  • structural_inference

Reproduce

inputs
17 source keys (listed under Sources)
plan
not recorded — template version, prompt hash and git SHA are written from 2026-09 onward
model
pipeline-v5
streams
none — agent transcripts are persisted from 2026-09 onward
20 searches — query, source, results, what was kept and why
20 searches for this run
#sourcequeryseenkeptrationale
1ClinicalTrials.gov · absencetetrahydrocannabihexol THCH0—No trials to include
2PubMedtetrahydrocannabihexol THCH cannabinoid66All 6 articles are directly relevant to THCH chemistry, pharmacology, or forensic detection
3PubChem · absencetetrahydrocannabihexol / delta-9-tetrahydrocannabihexol / THCH cannabinoid hexyl0—Will attempt web search to find PubChem CID
4OpenAlextetrahydrocannabihexol THCH174Selected high-citation papers with direct pharmacological and chemical relevance to THCH
5WebSearchTHCH tetrahydrocannabihexol legal status scheduling DEA US UK EU 2024102Legal status data for multiple jurisdictions
6ClinicalTrials.gov · absencetetrahydrocannabihexol THCH0—No trials to include
7WebSearchtetrahydrocannabihexol THCH PubChem CID molecular formula SMILES102Chemical identity data confirmed
8WebSearchTHCH tetrahydrocannabihexol adverse effects toxicity hospitalization case report 2023 2024102Safety and toxicity context
9PubChemCID 161906 (direct lookup)11Verified chemical identity for delta-9-THCH
10Japan National Consumer Affairs Center—11Primary safety/toxicology data from regulatory source
11WebSearchRoger Adams parahexyl n-hexyl THC synthesis 1942 1949 cannabinoid history101Important historical context for discovery/pre-history of THCH
12HandWikiTetrahydrocannabihexol chemistry page14Relevant pharmacological and historical references
13WebSearchTHCH tetrahydrocannabihexol CB1 Ki binding affinity nM receptor pharmacology published study100Confirmed gap: no published CB1 Ki values for THCH specifically
14PubMedRusso Vandelli HHC hexahydrocannabinol synthesis pharmacological epimers 202311Contextual pharmacology from same research group who discovered THCH
15Japan National Consumer Affairs Center—11Primary safety data
16PubMedsimilarities differences THC derivatives cannabinoid CB1 CB2 binding phytocannabinoids 202111CB1 receptor pharmacology context for THC derivatives
17WebSearchUK ACMD semi-synthetic cannabinoids THCH scheduling recommendation 2025101UK legal status data
18Multi-source · absenceTHCH CB1 Ki EC50 binding affinity cross-reference00Confirmed gap requiring flag in output
19Multiple sources synthesisTHCH legal status compilation45Legal status compilation for article
20HandWikiTetrahydrocannabihexol chemistry13Key chemical identity verification and history
51 claims by section — every cited sentence, checked against its source
pharmacology8 · 7 ok

  • In a β-arrestin2 recruitment bioassay covering 30 THC isomers, homologs, and analogs assessed across picomolar-to-micromolar concentration ranges, Janssens and colleagues identified THCH as one of multiple THC homologs demonstrating higher potential for CB1 activation than Δ9-THC, measured by either higher efficacy (Emax) or higher potency (lower EC50)supported

    Panel of 30 THC isomers/homologs/analogs assessed via CB1 β-arrestin2 recruitment bioassay. THCH identified as showing higher CB1 activation potential than Δ9-THC. s00204-024-03769-4

  • The C-3 alkyl side chain is the primary determinant of CB1 binding in classical cannabinoids: elongation from 5 to 6 carbons increases lipophilicity and deepens engagement with the CB1 receptor's hydrophobic pocketsupported

    Cumulative SAR studies define critical structural elements for potency and selectivity toward CB1 and CB2. pmc.s32171

  • Martin and colleagues demonstrated that chain length and flexibility are critical for agonist efficacy — short chains reduce potency, while extensions up to 7–8 carbons generally enhance it.supported

    SAR study of THC side chain modifications. Alkyl chain length crucial for CB receptor activation. pmid:10454479

  • As a full CB1 agonist, THCH is expected to signal via Gi/o-coupled pathways (adenylyl cyclase inhibition → decreased cAMP; MAPK/ERK activation) and β-arrestin2 recruitmentsupported

    Signaling studies include cAMP, MAPK, and beta-arrestin recruitment. j.phrs.2021.105970

  • As a full CB1 agonist, THCH is expected to signal via Gi/o-coupled pathways (adenylyl cyclase inhibition → decreased cAMP; MAPK/ERK activation) and β-arrestin2 recruitmentpartially supported

    Panel of 30 THC isomers/homologs/analogs assessed via CB1 β-arrestin2 recruitment bioassay. s00204-024-03769-4

  • Claim in pharmacology — inconclusiveinconclusiveworking →

  • Brown and Harvey (1988) administered both n-hexyl-Δ8-THC and n-hexyl-Δ9-THC (i.e., Δ8-THCH and Δ9-THCH) intraperitoneally to male Charles-River CD-1 mice and identified hepatic metabolites by GC/MS after Sephadex LH-20 chromatography. Δ9-THCH yielded 16 metabolites; Δ8-THCH yielded 11supported

    n-Hexyl-delta-8-THC and n-hexyl-delta-9-THC synthesized and administered IP to mice. 11 metabolites from delta-8 form, 16 from delta-9 form. pmid:2853671

  • Compared to the pentyl homolog, THCH metabolism showed a shift toward hydroxy metabolites at the expense of carboxylic acids, and dihydroxy metabolites appeared at low concentrations — a pattern absent in shorter-chain homologs but amplified in the heptyl homolog (THCP).supported

    More hydroxy metabolites relative to carboxylic acids compared to pentyl homolog, trend toward reduced oxidation with increasing chain length. pmid:2853671

safety8 · 6 ok

  • Products containing THCH are frequently sold as vaping liquidssupported

    First report of Δ9-THCH-O (THCH acetate) identification in commercially available electronic cigarette liquid products. dta.3777

  • Products containing THCH are frequently sold as vaping liquidssupported

    Analysis of five oil products distributed on the internet in Japan 2022-2023 claiming to contain THC analogs. Identified Δ8-THCH, Δ9-THCH. yakushi.24-00029

  • THCH acetate (THCH-O), identified in commercial e-cigarette products by Watanabe and colleagues, shares structural features with other acetylated cannabinoids that may generate ketene — a highly reactive toxicant — upon pyrolysispartially supported

    First report of Δ9-THCH-O (THCH acetate) identification in commercially available electronic cigarette liquid products. Compound isolated by semi-preparative HPLC and identified by NMR. dta.3777

  • Standard cannabinoid immunoassay (ELISA) screens show reduced cross-reactivity for extended-chain THC homologs including THCH compared to Δ9-THCsupported

    Increasing alkyl side-chain length relative to delta-9-THC results in decreased cross-reactivity. bkae036

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • By class inference from CB1 agonist pharmacology: repeated CB1 full agonism produces receptor downregulation and desensitisation via β-arrestin2-mediated receptor internalisation — the mechanism directly investigated by Janssens and colleagues for this compound class. Cross-tolerance with Δ9-THC and other CB1 agonists is expected given the shared receptor target.supported

    Panel of 30 THC isomers/homologs/analogs assessed via CB1 β-arrestin2 recruitment bioassay. THCH identified as showing higher CB1 activation potential than Δ9-THC. s00204-024-03769-4

  • Product contamination risk: Given documented mislabelling of THCH-containing products, consumers may be unknowingly exposed to additional unlabelled cannabinoids, making interaction risk assessment unreliable at the individual level.supported

    Products mislabelled — stated HHC/10-OH-HHC not detected. dta.3777

chemistry7 · 6 ok

  • Within this family, THCH is a homolog of Δ9-THC, differing exclusively in the length of the alkyl side chain at C-3: THCH carries a hexyl (6-carbon) chain where Δ9-THC carries a pentyl (5-carbon) chain.supported

    Compounds bear n-hexyl side chain on resorcinyl moiety. s41598-020-79042-2

  • Chain elongation systematically modulates CB1 receptor potency and lipophilicity, making each homolog pharmacologically distinct despite near-identical core structure.supported

    Cumulative SAR studies define critical structural elements for potency and selectivity toward CB1 and CB2. pmc.s32171

  • Both isomers have been detected in commercial products.supported

    Identified Δ8-THCH, Δ9-THCH in oil products distributed on the internet. yakushi.24-00029

  • The phenolic hydroxyl at C-1 and the C-3 hexyl chain are the primary pharmacophoric elements: the hydroxyl participates in hydrogen bonding at the CB1 receptor, while the alkyl chain occupies a hydrophobic groove whose depth tolerance determines potency.supported

    Review of structure-activity relationship of classical cannabinoids, examining five structural regions including C3 side chain. pmc.s32171

  • Claim in chemistry — inconclusiveinconclusiveworking →

  • Linciano and colleagues performed stereoselective synthesis to confirm the configuration of the naturally isolated material.supported

    Stereoselective synthesis performed for confirmation. s41598-020-79042-2

  • Δ9-THCH was isolated from the FM2 medicinal cannabis (Cannabis sativa L.) variety at very low concentrationssupported

    Reports discovery and characterisation of Δ9-THCH and cannabidihexol (CBDH) in FM2 medicinal cannabis variety. Semi-quantification in FM2 variety provided. s41598-020-79042-2

history6 · 5 ok

  • Linciano, Citti, Cannazza and colleagues at the University of Modena and Reggio Emilia reported the first isolation and structural characterisation of Δ9-THCH from the FM2 medicinal cannabis variety in 2020supported

    Reports discovery and characterisation of Δ9-THCH and cannabidihexol (CBDH) in FM2 medicinal cannabis variety. s41598-020-79042-2

  • The discovery followed the same group's 2019 identification of Δ9-THCP (heptyl chain) and Δ9-THCB (butyl chain) from the same variety.partially supported

    THCP isolated from FM2 cannabis variety with 7-carbon alkyl chain. s41598-019-56785-1

  • By 2021–2022, products claiming to contain Δ9-THC analogs with extended side chains appeared on online markets in Japan, Europe, and the United Statespartially supported

    Analysis of five oil products distributed on the internet in Japan 2022-2023 claiming to contain THC analogs. Identified Δ8-THCH, Δ9-THCH. yakushi.24-00029

  • Claim in history — inconclusiveinconclusiveworking →

  • Both Δ8-THCH and Δ9-THCH were identified in Japanese internet-distributed oil products from 2022–2023. Δ9-THCH acetate (Δ9-THCH-O) was first reported in commercially available e-cigarette liquids by Watanabe and colleagues in 2025supported

    Analysis of five oil products distributed on the internet in Japan 2022-2023 claiming to contain THC analogs. Identified Δ8-THCH, Δ9-THCH. yakushi.24-00029

  • Both Δ8-THCH and Δ9-THCH were identified in Japanese internet-distributed oil products from 2022–2023. Δ9-THCH acetate (Δ9-THCH-O) was first reported in commercially available e-cigarette liquids by Watanabe and colleagues in 2025supported

    First report of Δ9-THCH-O (THCH acetate) identification in commercially available electronic cigarette liquid products. dta.3777

receptor-pharmacology5 · 4 ok

  • The single most informative pharmacological study — a β-arrestin2 recruitment assay covering 30 THC-related compounds — established that THCH exhibits higher CB1 activation potential than Δ9-THC, manifesting as either greater efficacy (Emax) or greater potency (lower EC50), though specific numeric values for THCH were not extractable from the published abstract.supported

    Panel of 30 THC isomers/homologs/analogs assessed via CB1 β-arrestin2 recruitment bioassay. THCH identified as showing higher CB1 activation potential than Δ9-THC. s00204-024-03769-4

  • The monotonic potency increase with chain elongation — confirmed across multiple SAR studies — predicts that THCH's CB1 affinity falls between Δ9-THC (~40 nM) and Δ9-THCP (1.2 nM)supported

    Cumulative SAR studies define critical structural elements for potency and selectivity toward CB1 and CB2. pmc.s32171

  • The monotonic potency increase with chain elongation — confirmed across multiple SAR studies — predicts that THCH's CB1 affinity falls between Δ9-THC (~40 nM) and Δ9-THCP (1.2 nM)supported

    Alkyl chain length crucial for CB receptor activation. pmid:10454479

  • Claim in receptor-pharmacology — inconclusiveinconclusiveworking →

  • Janssens and colleagues specifically assessed β-arrestin2 recruitment as a functional readout of CB1 activation. β-arrestin2 recruitment is associated with receptor desensitisation and internalisation — processes central to tolerance developmentsupported

    Panel of 30 THC isomers/homologs/analogs assessed via CB1 β-arrestin2 recruitment bioassay. s00204-024-03769-4

summary5 · 4 ok

  • This single-carbon extension places THCH between Δ9-THC and Δ9-THCP (7-carbon) in the cannabinoid homologous series and confers higher CB1 receptor potency than Δ9-THCsupported

    THCH identified as showing higher CB1 activation potential than Δ9-THC. Structure-activity relationships assessed for Δ9-THC and Δ8-THC homologs with elongated alkyl chains. s00204-024-03769-4

  • First synthesized as parahexyl by Roger Adams in approximately 1941–1942, the compound was identified as a natural phytocannabinoid only in 2020 when Linciano and colleagues isolated it from the FM2 medicinal cannabis varietysupported

    Reports discovery and characterisation of Δ9-THCH and cannabidihexol (CBDH) in FM2 medicinal cannabis variety. s41598-020-79042-2

  • Claim in summary — not_supportednot supportedworking →

  • THCH acts as a full agonist at the cannabinoid CB1 receptor, signalling via Gi/o-coupled inhibition of cAMP and β-arrestin2 recruitmentpartially supported

    Panel of 30 THC isomers/homologs/analogs assessed via CB1 β-arrestin2 recruitment bioassay. THCH identified as showing higher CB1 activation potential than Δ9-THC. s00204-024-03769-4

  • No published Ki or EC50 values specific to THCH exist; its hexyl side chain is expected to produce binding affinity intermediate between Δ9-THC and Δ9-THCP (Ki = 1.2 nM) based on the established monotonic potency increase with chain elongationsupported

    Cumulative SAR studies define critical structural elements for potency and selectivity toward CB1 and CB2. pmc.s32171

comparative-pharmacology4 · 4 ok

  • The series demonstrates a broadly monotonic relationship between alkyl chain length and CB1 receptor potency:supported

    Cumulative SAR studies define critical structural elements for potency and selectivity toward CB1 and CB2. pmc.s32171

  • The series demonstrates a broadly monotonic relationship between alkyl chain length and CB1 receptor potency:supported

    Alkyl chain length crucial for CB receptor activation. pmid:10454479

  • This transition appears to occur between C5 and C6 chain lengths in the Δ9-THC series.supported

    THCH identified as showing higher CB1 activation potential than Δ9-THC. Structure-activity relationships assessed for Δ9-THC and Δ8-THC homologs with elongated alkyl chains. s00204-024-03769-4

  • Tolerance kinetics: Full agonists recruit β-arrestin2 more efficiently, potentially accelerating receptor downregulation and tolerance developmentsupported

    Panel of 30 THC isomers/homologs/analogs assessed via CB1 β-arrestin2 recruitment bioassay. s00204-024-03769-4

clinical-evidence3 · 3 ok

  • Mouse metabolism studies (Brown and Harvey 1988)supported

    n-Hexyl-delta-8-THC and n-hexyl-delta-9-THC synthesized and administered IP to mice. pmid:2853671

  • In vitro CB1 receptor pharmacology via β-arrestin2 recruitment assay (Janssens et al. 2024)supported

    Panel of 30 THC isomers/homologs/analogs assessed via CB1 β-arrestin2 recruitment bioassay. s00204-024-03769-4

  • Structural characterisation and semi-quantification in cannabis (Linciano et al. 2020)supported

    Reports discovery and characterisation of Δ9-THCH...Semi-quantification in FM2 variety provided. s41598-020-79042-2

pharmacokinetic-detail3 · 3 ok

  • The sole published metabolic study was conducted in male CD-1 mice receiving intraperitoneal administration of n-hexyl-Δ8-THC and n-hexyl-Δ9-THC.supported

    n-Hexyl-delta-8-THC and n-hexyl-delta-9-THC synthesized and administered IP to mice. pmid:2853671

  • LC-MS/MS (Muir et al. 2025): Qualitative identification of Δ8-THCH in urine and quantitative confirmation in blood, with a limit of detection (LOD) of 1 ng/mL for parent compounds. Δ9-THCH is also detectable in blood.partially supported

    Includes THCH (Δ8-THCH in urine only)...LOD 1 ng/mL for non-carboxylated analytes. bkaf023

  • LC-QTOF-MS (Schirmer et al. 2025): Rapid screening method validated for 24 semi-synthetic cannabinoids in whole blood (LOD range 0.8–16 ng/mL), with THCH included among target analytes.supported

    Validated LC-QTOF-MS screening for 24 phytocannabinoids and semi-synthetic cannabinoids in blood. Recovery 87-118%, LOD 0.8-16 ng/mL. Includes THCH among analytes. bkaf095

legal-status1 · 1 ok

  • The compound's legal classification varies significantly by jurisdiction, and the regulatory framework continues to shift as governments respond to the broader emergence of semi-synthetic cannabinoids.supported

    Review of CBD-derived psychoactive cannabinoids sold in semi-legal market after 2018 Farm Bill. Discusses THCH among compounds, notes lack of regulatory oversight, unknown pharmacology, and public health risks. 000536339

neuroscience1 · 1 ok

  • The following is derived from the established neuroscience of CB1 receptor activation, which THCH engages as a full agonist.supported

    THCH identified as showing higher CB1 activation potential than Δ9-THC. s00204-024-03769-4

3Sources

17 consumed · sorted by year · feeds = sections resting on it

Sources
yearsourcetierstatusfeeds
2025Comprehensive LC-MS-MS analysis of THC isomers, analogs, homologs, and metabolites in blood and urineMuir LS, Doumit SE, Seither JZ, Knittel JL, Walterscheid JP, Karschner EL · Journal of Analytical Toxicologydoi:10.1093/jat/bkaf023moderateconsumed2 sections
2025Discrepancies between the stated contents and analytical findings for electronic cigarette liquid products: Identification of the new cannabinoid, Δ9-tetrahydrocannabihexol acetateWatanabe S, Murakami T, Muratsu S, Fujiwara H, Nakanishi T, Seto Y · Drug Testing and Analysisdoi:10.1002/dta.3777moderateconsumed3 sections
2025Rapid LC-QTOF-MS screening method for semi-synthetic cannabinoids in whole bloodSchirmer W, Walton SE, Weinmann W, Schürch S, Logan BK · Journal of Analytical Toxicologydoi:10.1093/jat/bkaf095strongconsumed2 sections
2025Semi-synthetic cannabinoids related to tetrahydro-cannabinol and cannabidiol — ACMD report and government responseAdvisory Council on the Misuse of Drugs (ACMD), UK Governmenturl:e3a06ae8877bbd1cweakconsumedcited only
2024Cannabidiol-Derived Cannabinoids: The Unregulated Designer Drug Market Following the 2018 Farm BillZawatsky CN, Mills-Huffnagle S, Augusto CM, Vrana KE, Nyland JE · Medical Cannabis and Cannabinoidsdoi:10.1159/000536339moderateconsumed1 section
2024Cross-reactivity of 24 cannabinoids and metabolites in blood using the Immunalysis Cannabinoids Direct enzyme-linked immunosorbent assayPatton AL, Pacheco IC, Seither JZ, Brown JT, Walterscheid JP, Karschner EL · Journal of Analytical Toxicologydoi:10.1093/jat/bkae036strongconsumed1 section
2024Identification of Δ8-THC and Δ9-THC Analogs with Different Alkyl Chain Lengths in Oil Products Distributed on the InternetTanaka R, Kikura-Hanajiri R · Yakugaku Zasshi: Journal of the Pharmaceutical Society of Japandoi:10.1248/yakushi.24-00029moderateconsumed3 sections
2024Investigation of the intrinsic cannabinoid activity of hemp-derived and semisynthetic cannabinoids with β-arrestin2 recruitment assays - and how this matters for the harm potential of seized drugsJanssens LK, Van Uytfanghe K, Williams JB, Hering KW, Iula DM, Stove CP · Archives of Toxicologydoi:10.1007/s00204-024-03769-4moderateconsumed7 sections
2023Cannabinoid THCH is designated substance! Never obtain and use products including THCHNational Consumer Affairs Center of Japanurl:414164d7caaece3fweakconsumedcited only
2021Cannabinoids, Phenolics, Terpenes and Alkaloids of CannabisRadwan MM, Chandra S, Gul S, ElSohly MA · Moleculesdoi:10.3390/molecules26092774moderateconsumedcited only
2021Similarities and differences upon binding of naturally occurring Δ9-tetrahydrocannabinol-derivatives to cannabinoid CB1 and CB2 receptorsRaïch I, Rivas-Santisteban R, Lillo A, et al. · Pharmacological Researchdoi:10.1016/j.phrs.2021.105970strongconsumed1 section
2020Identification of a new cannabidiol n-hexyl homolog in a medicinal cannabis variety with an antinociceptive activity in mice: cannabidihexolLinciano P, Citti C, Russo F, Tolomeo F, Laganà A, Capriotti AL, Luongo L, Iannotta M, Belardo C, Maione S, Forni F, Vandelli MA, Gigli G, Cannazza G · Scientific Reportsdoi:10.1038/s41598-020-79042-2strongconsumed4 sections
2019A novel phytocannabinoid isolated from Cannabis sativa L. with an in vivo cannabimimetic activity higher than Δ9-tetrahydrocannabinol: Δ9-TetrahydrocannabiphorolCitti C, Linciano P, Russo F, Luongo L, Iannotta M, Maione S, Laganà A, Capriotti AL, Forni F, Vandelli MA, Gigli G, Cannazza G · Scientific Reportsdoi:10.1038/s41598-019-56785-1strongconsumed1 section
2016The Structure-Function Relationships of Classical Cannabinoids: CB1/CB2 ModulationBow EW, Rimoldi JM · Perspectives in Medicinal Chemistrydoi:10.4137/pmc.s32171moderateconsumedcited only
1999Manipulation of the tetrahydrocannabinol side chain delineates agonists, partial agonists, and antagonistsMartin BR, Jefferson R, Winckler R, Wiley JL, Huffman JW, Crocker PJ, Saha B, Razdan RK · Journal of Pharmacology and Experimental Therapeuticspmid:10454479moderateconsumed3 sections
1988Metabolism of n-hexyl-homologues of delta-8-tetrahydrocannabinol and delta-9-tetrahydrocannabinol in the mouseBrown NK, Harvey DJ · European Journal of Drug Metabolism and Pharmacokineticspmid:2853671moderateconsumed3 sections
1946Parahexyl (Synhexyl) — synthesis and early pharmacological historyMultiple sources (Grokipedia, en-academic.com, medbox.iiab.me summaries of Adams/Loewe work)url:37526dc53c27b158weakconsumedcited only
—Searched ClinicalTrials.gov for "tetrahydrocannabihexol THCH" — no resultsabsenceno results—
—Searched ClinicalTrials.gov for "tetrahydrocannabihexol THCH" — no resultsabsenceno results—
—Searched Multi-source for "THCH CB1 Ki EC50 binding affinity cross-reference" — no resultsabsenceno results—
—Searched PubChem for "tetrahydrocannabihexol / delta-9-tetrahydrocannabihexol / THCH cannabinoid hexyl" — no resultsabsenceno results—

4Docket

one filing per activity — decisions, correspondence, reports

  1. 0012026-05-13revisionRevision 1

    Initial LLM generation (v5 pipeline, wiki, prose phase)

    psx:substance/tetrahydrocannabihexol/version/1
  2. 0022026-06-04proposal16 value proposals approved together

    one review action inferred from a shared reviewer and instant — the graph records one activity per proposal

    16 items in this filing

    • contraindication · pregnancy_breastfeeding
    • contraindication · cardiovascular
    • contraindication · psychiatric
    • contraindication · other
    • contraindication · hepatic
    • contraindication · age
    • toxicity
    • dependence · full
    • withdrawal
    • tolerance
    • dose_tier · threshold
    • dose_tier · light
    • dose_tier · common
    • dose_tier · strong
    • dose_tier · heavy
    psx:substance/tetrahydrocannabihexol/proposal/contraindication/8bed2d0a-1b30-421f-ae11-c526ee360400
  3. 0032026-06-04publicationPublication — backfill
    psx:substance/tetrahydrocannabihexol/pub/d53c3392-d8d4-424d-a87c-0211cea9b8a6

5Issued documents

what the notice, info card and emergency page said, by hash

Issued documents
documentcontent hashissuedfrom versionsuperseded
emergency7386375eac1334714f070b93…2026-10-19 20:34Revision 1current
info_card4a6ebe242359309da0e5d80d…2026-10-19 20:34Revision 1current
emergency207cf682e28a91d88136b9a2…2026-09-04 04:32Revision 1superseded2026-10-19
info_card588d291229c8e623be905bb3…2026-09-04 04:32Revision 1superseded2026-10-19
noticebe4a9d59ca1428869e13d168…2026-09-04 04:32Revision 1current